Mallinckrodt PLC (MNK)

76.31
NYSE : Health Care
Prev Close 74.38
Day Low/High 74.19 / 76.81
52 Wk Low/High 50.90 / 85.83
Avg Volume 1.61M
Exchange NYSE
Shares Outstanding 107.71M
Market Cap 8.01B
EPS 2.80
P/E Ratio 16.17
Div & Yield N.A. (N.A)

Latest News

Mallinckrodt (MNK) Stock Price Target Reduced at Deutsche Bank

Mallinckrodt (MNK) Stock Price Target Reduced at Deutsche Bank

Mallinckrodt's (MNK) stock price target was lowered to $84 from $87 at Deutsche Bank.

5 Health Care Stocks John Paulson Is Betting On in 2016

5 Health Care Stocks John Paulson Is Betting On in 2016

When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.

Big Pharma's Punishment in Court of Public Opinion

Big Pharma's Punishment in Court of Public Opinion

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Big Pharma Has No Rx for Viral Social Media Reactions

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

Andrew Left Says Mallinckrodt's Key Drug Could Be in Jeopardy

Andrew Left Says Mallinckrodt's Key Drug Could Be in Jeopardy

The drugmaker could be at risk as regulators begin to crack down on price hikes, Andrew Left says.

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny

Short-seller Andrew Left says Mallinckrodt has long been gaming the system on its Acthar Gel drug.

Mallinckrodt's Top Drug Could Go the Way of EpiPen

Mallinckrodt's Top Drug Could Go the Way of EpiPen

The drug that's helping boost the company's stock could become its biggest risk.

Mallinckrodt Receives FDA Fast-Track Designation For Synacthen® Depot IND Application

Mallinckrodt Receives FDA Fast-Track Designation For Synacthen® Depot IND Application

-- Expedites potential treatment for Duchenne muscular dystrophy --

Mallinckrodt (MNK) Stock Climbs on Nuclear Imaging Business Sale

Mallinckrodt (MNK) Stock Climbs on Nuclear Imaging Business Sale

Mallinckrodt (MNK) stock was trading higher this morning as it will receive about $690 million for its nuclear imaging business.

Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million

Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million

-- Transaction advances Mallinckrodt's strategic portfolio transformation to specialty pharmaceuticals -

Cramer: 16 Things I Am Watching Right Now

Cramer: 16 Things I Am Watching Right Now

Here are some things that could move stock prices today.

Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products

Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products

-- Acquisition further diversifies Mallinckrodt's hospital portfolio pipeline --

Mallinckrodt Takes Over #5 Spot From Lam Research

Mallinckrodt Takes Over #5 Spot From Lam Research

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Mallinckrodt plc has taken over the #5 spot from Lam Research Corp , according to ETF Channel. Below is a chart of Mallinckrodt plc versus Lam Research Corp plotting their respective rank within the S&P 500 over time (MNK plotted in blue; LRCX plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Mallinckrodt (MNK) Stock Soars on Q3 Results, Outlook

Mallinckrodt (MNK) Stock Soars on Q3 Results, Outlook

Mallinckrodt (MNK) stock is jumping late Tuesday afternoon after the biopharma company posted solid results for the 2016 fiscal third quarter and raised its guidance.

Trending Tickers: MNK, FTR, DISCA, CVS

Trending Tickers: MNK, FTR, DISCA, CVS

Markets were falling as oil prices continued their two-month descent below $40 a barrel.

Watch Out: Barbarians At The Gate For Mallinckrodt (MNK)

Watch Out: Barbarians At The Gate For Mallinckrodt (MNK)

Trade-Ideas LLC identified Mallinckrodt (MNK) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

First Patient Enrolled In Mallinckrodt Phase 3 Terlipressin Trial

First Patient Enrolled In Mallinckrodt Phase 3 Terlipressin Trial

-- Mallinckrodt's CONFIRM Study to Assess Efficacy and Safety of Terlipressin in Hepatorenal Syndrome Type 1--

The New #32 Most Shorted S&P 500 Component: Mallinckrodt

The New #32 Most Shorted S&P 500 Component: Mallinckrodt

The most recent short interest data has been released for the 07/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Strong On High Volume: Mallinckrodt (MNK)

Strong On High Volume: Mallinckrodt (MNK)

Trade-Ideas LLC identified Mallinckrodt (MNK) as a strong on high relative volume candidate

Barbarian At The Gate: Mallinckrodt (MNK)

Barbarian At The Gate: Mallinckrodt (MNK)

Trade-Ideas LLC identified Mallinckrodt (MNK) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Health Care Resource Use And Costs Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Multiple Sclerosis Relapse

Health Care Resource Use And Costs Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Multiple Sclerosis Relapse

- Retrospective Health Economic Data Published in Advances in Therapy Show Acthar May Be an Important Treatment Option for Patients with Multiple Sclerosis Relapses -

Trending Tickers: UAL, MNK, ENDP, BWA

Optimism that the United Kingdom will remain part of the EU was tempered by falling oil prices.

Mallinckrodt Needs More Medicine

A rally above $65 with strong volume is needed to change the direction of MNK.